Gail Fowler Joins Rho As Vice President Of Operations

Chapel Hill, NC – (November 18, 2013) – Gail Fowler joins Rho today as vice president of operations, bringing nearly 30 years of clinical research experience. Ms. Fowler's most recent position was vice president of clinical operations and clinical trial management for ICON Clinical Research based in Durham, NC.

"I am excited to bring Gail's leadership and clinical research experience to Rho," said Laura Helms Reece, Dr. P.H., chief executive officer for Rho. "Combining Gail's knowledge and judgment and our great people will allow Rho to continue to improve our exceptional customer experience."

In this position, Ms. Fowler will lead a growing team of research professionals, including project managers, clinical research associates, data managers, biostatisticians, statistical programmers and program managers. The addition of Ms. Fowler represents a continued commitment by Rho to attract and retain the highest caliber employees in the field of clinical research and development. 

About Rho

Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For more than 25 years, Rho has been a trusted partner to some of the industry's leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Twitter. 

Suggested Articles

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.